Telix Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration 2025-12-11 03:30
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed 2025-12-08 06:08
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held 2025-11-21 14:22
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses 2025-11-20 03:00
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer 2025-11-12 04:00
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging 2025-10-23 19:00
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain 2025-10-23 04:00
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded 2025-10-14 14:59
Telix Announces Record-Breaking Presence at EANM 2025 2025-10-01 13:57
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis 2025-09-10 07:01
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth 2025-08-21 08:23
Telix H1 2025 Results: Investor Webcast Notification 2025-07-30 07:00
Telix Reports $204M Revenue, Up 63% YOY 2025-07-22 16:02
Gozellix Receives Permanent HCPCS Code 2025-07-09 12:41
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan 2025-06-04 06:30
Telix at ANZSNM Annual Scientific Meeting 2025 2025-05-20 06:00
Illuccix China Phase 3 Study Completes Enrolment 2025-05-13 07:22
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy 2025-05-08 05:00
Telix's Illuccix PSMA-PET Imaging Agent Approved in France 2025-04-29 06:30
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate 2025-04-16 06:45
1 2 3 4 5 9